Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
r
eports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Idiopathic Pulmonary Fibrosis: KOL Insight
    Learn More Idiopathic Pulmonary Fibrosis: KOL Insight
    Roche’s Esbriet, (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) are the only approved therapies for Idiopathic Pulmonary Fibrosis (IPF). Will either be able to establish themselves as first...
  • Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
    Learn More Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
    Combination therapy is set to take centre stage in the treatment of COPD as leading companies such as GlaxoSmithKline (GSK), Boehringer Ingelheim and AstraZeneca vie for market position and share. But will clinicians,...
  • Nonalcoholic Steatohepatitis: KOL Insight
    Learn More Nonalcoholic Steatohepatitis: KOL Insight
    Why This Report is Essential KOL Views Covered Expect a revolution in the treatment of nonalcoholic steatohepatitis (NASH) as a number of new therapies compete to become the first approved treatment...
  • Ovarian Cancer: KOL Insight
    Learn More Ovarian Cancer: KOL Insight
    Ovarian Cancer: KOL Insight, A new era of targeted therapy provides leading clinician insights on new ovarian cancer (OC) drugs at a time of significant change in the therapy landscape. Why This Report is...
  • Renal Cell Carcinoma: KOL Insight
    Learn More Renal Cell Carcinoma: KOL Insight
    Will new checkpoint inhibitors revive immunotherapy in RCC? Renal Cell Carcinoma: KOL Insight offers opinions of 12 leading US and European KOLs that present business-critical insights for branded pharma and the drug...
  • Ulcerative Colitis: KOL Insight_OLD
    Learn More Ulcerative Colitis: KOL Insight_OLD
    The Ulcerative Colitis (UC) treatment market is already undergoing radical change as new, safer products that slow disease progression have come to market or will be launched in the next few years.  While 5-ASA and...
  • HIV: KOL Insight
    Learn More HIV: KOL Insight
    HIV: KOL Insight examines what frontline clinicians really think about current HIV treatment pathways, addresses the most pressing unmet needs the industry can respond to and gives insight into what's driving long term...
  • Hepatitis C: Payer Insights
    Learn More Hepatitis C: Payer Insights
    The race is on for the company that can competitively price treatment regimens, share data on clinical benefit/positioning and support patient initiatives.  Payer Insights: Hepatitis C, based on in-depth interviews...
  • HIV: KOL Insight  and Consensus Outlook
    Learn More HIV: KOL Insight and Consensus Outlook
    HIV: KOL Insight and Consensus Outlook examines what frontline clinicians really think about current HIV treatment pathways, addresses the most pressing unmet needs the industry can respond to and gives insight into...
  • Diabetes: KOL Insight and Consensus Outlook
    Learn More Diabetes: KOL Insight and Consensus Outlook
    FirstWord’s Therapy Trends: Diabetes offers a complete ongoing analysis of current trends, future forecasts and landscape modifiers. Gain instant access to an accurate, unbiased, qualitative review of the latest...
  • Hepatitis C: KOL Insight and Consensus Outlook
    Learn More Hepatitis C: KOL Insight and Consensus Outlook
    Approval of Gilead’s once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy...
  • Hepatitis C: Consensus Outlook
    Learn More Hepatitis C: Consensus Outlook
    The worldwide hepatitis C (HCV) market is forecasted to grow to $17.7 billion in 2017.  The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more...
  • Colorectal Cancer: KOL Insight
    Learn More Colorectal Cancer: KOL Insight
    The global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be...
  • Diabetes: Consensus Outlook
    Learn More Diabetes: Consensus Outlook
    Therapy Trends Consensus Outlook: Diabetes is an in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and...
  • Diabetes: KOL Insight
    Learn More Diabetes: KOL Insight
    Therapy Trends KOL Insight: Diabetes analyses the current and predicted key issues, current products and late-stage pipeline product and gives you qualitative information based on exclusive interviews with 12 key...
  • Alzheimer’s disease: KOL Insight
    Learn More Alzheimer’s disease: KOL Insight
    In 2012, the Alzheimer’s disease (AD) market was dealt a huge blow following negative results from pivotal Phase III trials of Pfizer and J&J’s bapineuzumab and the intravenous formulation of the drug was...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved